®th IRVING, Texas, Jan. 5, 2026 /PRNewswire/ -- Caris Life Sciences (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the 44 Annual J.P. Morgan Healthcare Conference, which will be held January 12-15, 2026, in San Francisco, California. Caris will present and participate in a Q&A session on Monday, January 12 at 1:30 PM PT. Live and replay webcasts will be available on the Investor Relations section ...

Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer focused on transforming healthcare through innovative solutions [2] - The company specializes in comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing, and utilizes advanced AI and machine learning algorithms to analyze complex disease data [2] - Caris has developed a large-scale, multimodal clinico-genomic database and computing capability to enhance precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection, and drug development [2] Financial Performance - Caris Life Sciences reported its third quarter 2025 financial results and increased its revenue guidance for the year [3] Upcoming Events - The company will attend several investor conferences, including Wolfe Research's 7th Annual Healthcare Conference on November 18, Citi's 2025 Global Healthcare Conference on December 3, and the 8th Annual Evercore Healthcare Conference on December 4 [4]

Core Insights - Caris Life Sciences has identified TET2 clonal hematopoiesis (CH) as a promising biomarker for improved response to immune checkpoint inhibitor (ICI) therapy in patients with solid tumors [1][3] - The study, led by Dr. Padmanee Sharma, utilized TET2-mutant laboratory models to explore how these mutations influence immune dynamics within the tumor microenvironment [2] - The research analyzed outcomes from nearly 36,000 non-small cell lung cancer (NSCLC) patients and over 25,000 colorectal cancer (CRC) patients, providing substantial evidence supporting TET2-CH as a potential biomarker for enhanced ICI response [3] Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, developing innovative solutions to transform healthcare through comprehensive molecular profiling and advanced AI applications [6] - The company has created a large-scale, multimodal clinico-genomic database to analyze the molecular complexity of diseases, enhancing early detection, diagnosis, monitoring, therapy selection, and drug development [6][7] - Caris operates internationally with offices in multiple locations, including the U.S., Japan, and Switzerland, and aims to realize the potential of precision medicine to improve human health [7]

Core Insights - Caris Life Sciences will present six studies at the ESMO Congress 2025, showcasing the impact of multiomics in precision medicine and cancer treatment [1][2][3] Research Highlights - The studies involve collaboration with over 25 leading cancer centers globally, emphasizing Caris' leadership in next-generation sequencing and biomarker discovery [2][7] - Tumor types covered include colorectal, gastric, breast, pancreatic, head & neck, prostate, urothelial, renal, and biliary tract cancers [2] Presentation Formats - The research will be presented in various formats: one oral "Proffered Paper," one mini-oral, and four poster presentations [2] - Key presentations include topics on Mismatch Repair Deficiency and its implications for immune checkpoint blockade [3][4] Company Overview - Caris Life Sciences is a pioneer in precision medicine, utilizing advanced AI and machine learning to enhance molecular profiling and cancer treatment [9][10] - The company aims to improve clinical outcomes through innovative research and collaboration within the Caris Precision Oncology Alliance, which includes 97 cancer centers [7]

Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer [2] - The company is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [3] - Caris provides services in the U.S. and other international markets through its own operations and distributor partners [3] Financial Reporting - Caris Life Sciences will report its second quarter 2025 financial results on August 12, 2025 [1] - A conference call and live webcast will be held at 3:30 p.m. CT (4:30 p.m. ET) to discuss these financial results [1] - A replay of the webcast will be available shortly after the call on the Investor Relations section of the Caris Life Sciences website [1] Technological Capabilities - The company utilizes comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing, combined with advanced AI and machine learning algorithms [2] - Caris has developed a large-scale, multimodal clinico-genomic database and computing capability to analyze the molecular complexity of diseases [2] - This integration of next-generation sequencing, AI, machine learning technologies, and high-performance computing enables the development of advanced precision medicine diagnostic solutions [2]